Greetings Purism Investor!
We’re excited to offer two opportunities to invest in Purism at this time:
-
Private Placement to purchase Common Shares
Offering share purchasing at $5.55 (up from $4.00 in 2024 offering).
Purism – Investor Relations – Private Placement
This investment is for those that desire to be an equity holder in a long-term investment tied to the growth and success of Purism. This offer is for private placement and will not be offered outside this newsletter or private email. Yes, you can share the offer with others.
Purism is in a strong position to consider all long term exit possibilities, IPO, dividend payouts, acquisition, stock buy back, reinvest to grow the business. Our current focus continues to be reinvest to grow the business and will be the focus throughout 2025 and 2026.
-
Revenue Share Asset Backed Loan (refinance)
Offering 9% APR interest on an asset backed loan, payable from future sale of product.
Purism – Investor Relations – Revenue Share Asset Backed Loan
This is for those that desire to be a debt holder in a shorter-term investment tied to the revenue earned from product sales by Purism.
Purism holds a lot of assets, this particular asset set aside is for Librem 5 v1 products actively being sold, and the time-frame for debt payoff would be within two years.
In addition to the above offerings we have other areas we are advancing:
- Clearing debts and operating on a balanced budget.
- Large equity investment from two strategic investment groups continues to advance.
- Development and upcoming new release of PureOS is on target.
- We have demos in June for three federal agencies on Made in USA Electronics and Post Quantum Cryptography.
- We are soon to update the My Account page to include Investment status for ease of observing and managing your investments, stay tuned for that separate announcement.
There will be more news coming, product iterations, sales updates, and investment opportunities.
Stay tuned for more news coming in 2025. Thank you for your continued support!
– Purism Investor Relations